<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Revefenacin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Revefenacin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Revefenacin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="119702" href="/d/html/119702.html" rel="external">see "Revefenacin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52143853"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Yupelri</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F52111412"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent;</li>
<li>
                        Anticholinergic Agent, Long-Acting</li></ul></div>
<div class="block doa drugH1Div" id="F52161100"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c6f4720-28f3-4c2d-84c9-7afdfa8fd1a7">Chronic obstructive pulmonary disease, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic</b>
<b> obstructive pulmonary disease, maintenance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Depending on symptoms and exacerbation risk, use monotherapy long-acting bronchodilator (long-acting beta agonist or long-acting muscarinic antagonist). In patients with more symptoms (eg, group B), use in combination with long-acting beta agonist. In addition, a short-acting bronchodilator is used for intermittent symptom relief (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gold.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gold.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution: <b>Oral inhalation: </b>175 mcg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information</p></div>
<div class="block dora drugH1Div" id="F52161102"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F52161103"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Mild, moderate, or severe impairment: Use is not recommended.</p></div>
<div class="block doe drugH1Div" id="F52161101"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F52144199"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (1% to &lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1% to &lt;2%), headache (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (1% to &lt;2%), nasopharyngitis (4%), oropharyngeal pain (1% to &lt;2%), upper respiratory tract infection (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Gastrointestinal: Xerostomia</p></div>
<div class="block coi drugH1Div" id="F52111415"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to revefenacin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F52161083"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Paradoxical bronchospasm that may be life-threatening and may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response. If paradoxical bronchospasm occurs, manage with a short-acting bronchodilator, discontinue revefenacin, and institute alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: Anticholinergic agents may cause dizziness and blurred vision; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Immediate hypersensitivity reactions may occur. Discontinue therapy immediately if an allergic reaction occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with narrow-angle glaucoma; may increase intraocular pressure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use is not recommended in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/bladder neck obstruction: Use with caution in patients with prostatic hyperplasia or bladder neck obstruction; may cause and/or worsen urinary retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Monitor for systemic antimuscarinic adverse effects in patients with severe renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Revefenacin is intended as a once daily maintenance treatment and is not indicated for the initial (rescue) treatment of acute episodes of bronchospasm or with acutely deteriorating or potentially life-threatening COPD; after initiation of therapy, patients should use short-acting bronchodilators only on an as needed basis for acute symptoms. COPD may deteriorate acutely (over hours) or chronically (over days or longer); if revefenacin no longer controls bronchoconstriction symptoms, short-acting beta2-agonists becomes less effective, or the more inhalations of a short-acting beta2-agonist than usual are required, these may be indicators of COPD deterioration; re-evaluate the COPD treatment regimen. Increasing the daily revefenacin dose beyond the recommended dose is not appropriate in this situation.</p></div>
<div class="block foc drugH1Div" id="F52143854"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yupelri: 175 mcg/3 mL (3 mL)</p></div>
<div class="block geq drugH1Div" id="F52143852"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52184947"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Yupelri Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">175 mcg/3 mL (per mL): $17.35</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F52161105"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral inhalation:</b> Nebulization solution: For oral inhalation only; do not inject or swallow solution. Administer by oral inhalation via a standard jet nebulizer with a mouthpiece connected to an air compressor. Remove the unit-dose vial from foil pouch immediately before use. Revefenacin does not require dilution prior to administration; compatibility with other medications (eg, formoterol) in nebulizer has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32401744','lexi-content-ref-32324981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32401744','lexi-content-ref-32324981'])">Ref</a></span>); also refer to institution-specific policies. Discard any used portion.</p></div>
<div class="block meg drugH1Div" id="F52144174"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F210598s000lbl.pdf%23page%3D16&amp;token=LKbR71%2BOZGwnMzT6UHRIb7F5Mw5Y6exwmDI09JNA06aDYKJA3gRa7dqrDus1Xxxk9jMqaMIWnazOqRYA%2Bdk57%2B1LoJcYwaDCp0n3MEmQA%2F94TZJ4Py2ite4nFN8qLmPn&amp;TOPIC_ID=119622" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf#page=16</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F52111414"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Chronic obstructive pulmonary disease, maintenance:</b> Maintenance treatment of chronic obstructive pulmonary disease.</p></div>
<div class="block mst drugH1Div" id="F52161078"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Revefenacin may be confused with darifenacin, Revlimid</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F52161008"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, OATP1B1/1B3 (SLCO1B1/1B3), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F52161005"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the anticholinergic effect of Revefenacin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Long-acting muscarinic antagonists (LAMAs) may diminish the therapeutic effect of Methacholine.  Management: Hold long-acting muscarinic antagonists (LAMAs) for at least 7 days before methacholine use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors: May increase serum concentrations of the active metabolite(s) of Revefenacin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54208248"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Females of reproductive potential were not included in original studies (Pudi 2017; Quinn 2017).</p></div>
<div class="block pri drugH1Div" id="F52161081"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F52161082"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if revefenacin is present in breast milk following oral inhalation.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F52161107"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">FEV<sub>1</sub>, peak flow (or other pulmonary function tests). Monitor for signs/symptoms of acute narrow angle glaucoma, hypersensitivity reactions, and urinary retention. Monitor for systemic antimuscarinic adverse effects in patients with severe renal impairment.</p></div>
<div class="block pha drugH1Div" id="F52161086"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Revefenacin is a long-acting muscarinic antagonist which competitively and reversibly inhibits the action of acetylcholine at type 3 muscarinic (M<sub>3</sub>) receptors in bronchial smooth muscle causing bronchodilation.</p></div>
<div class="block phk drugH1Div" id="F52161087"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Bronchodilation onset is within 45 minutes after a single dose and peak FEV<sub>1</sub> effect is 2 to 3 hours following a single dose (Quinn 2018)</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Bronchodilation: Up to 24 hours (Quinn 2018)</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid (Quinn 2018)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Revefenacin: ~71%; Active metabolite: ~42%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily metabolized via hydrolysis of the primary amide to carboxylic acid (to the major active metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: &lt;3%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 22 to 70 hours (revefenacin and active metabolite)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 14 to 41 minutes (after start of nebulization)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (primarily); Urine (&lt;1%, as revefenacin and active metabolite)</p></div>
<div class="block phksp drugH1Div" id="F52161097"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with severe impairment (CrCl &lt;30 mL/minute), revefenacin C<sub>max</sub> and AUC<sub>inf</sub> increased 1.5-fold and up to 2.3-fold respectively, and active metabolite C<sub>max</sub> and AUC<sub>inf</sub> increased up to 2-fold and 2.5-fold, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with moderate impairment (Child-Pugh score of 7 to 9), AUC of revefenacin increased 1.2-fold, and C<sub>max</sub> and AUC of active metabolite increased 1.5-fold and up to 4.7-fold respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54096817"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Yupelri</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Yupelri</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Gold.1">
<a name="Gold.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32401744">
<a name="32401744"></a>Ngim K, Patel J. Physicochemical stability and compatibility of revefenacin (LAMA) and formoterol fumarate (LABA) inhalation solution admixture. <i>Int J Pharm Compd</i>. 2020;24(3):242-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/revefenacin-drug-information/abstract-text/32401744/pubmed" id="32401744" target="_blank">32401744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29096627">
<a name="29096627"></a>Pudi KK, Barnes CN, Moran EJ, Haumann B, Kerwin E. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. <i>Respir Res.</i> 2017;18(1):182. doi: 10.1186/s12931-017-0647-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/revefenacin-drug-information/abstract-text/29096627/pubmed" id="29096627" target="_blank">29096627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28987804">
<a name="28987804"></a>Quinn D, Barnes CN, Yates W, et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. <i>Pulm Pharmacol Ther</i>. 2018;48:71-79. doi: 10.1016/j.pupt.2017.10.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/revefenacin-drug-information/abstract-text/28987804/pubmed" id="28987804" target="_blank">28987804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32324981">
<a name="32324981"></a>Siler TM, Moran EJ, Barnes CN, Crater GD. Safety and efficacy of revefenacin and formoterol in sequence and combination via a standard jet nebulizer in patients with chronic obstructive pulmonary disease: a phase 3b, randomized, 42-day study. <i>Chronic Obstr Pulm Dis</i>. 2020;7(2):99-106. doi:10.15326/jcopdf.7.2.2019.0154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/revefenacin-drug-information/abstract-text/32324981/pubmed" id="32324981" target="_blank">32324981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yupelri.1">
<a name="Yupelri.1"></a>Yupelri (revefenacin) [prescribing information]. Morgantown, WV: Mylan Specialty LP; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yupelri.2">
<a name="Yupelri.2"></a>Yupelri (revefenacin) [prescribing information]. Morgantown, WV: Mylan Specialty LP; May 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 119622 Version 99.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
